Trial Profile
The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive Symptoms in 80 Patients With Unipolar or Bipolar Depression: a Phase II Exploratory add-on Double Blind Placebo Controlled 2 Week Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2021
Price :
$35
*
At a glance
- Drugs JNJ 39393406 (Primary)
- Indications Bipolar depression; Depressive disorders
- Focus Therapeutic Use
- Acronyms JNJ-DEP
- 20 May 2021 Primary endpoint (Brief Assessment of Cognition in Schizophrenia (BACS) composite and the Montgomery-Asperg Depression Rating Scale (MADRS) scores) has not been met according to the results published in the European Neuropsychopharmacology
- 20 May 2021 Results published in the European Neuropsychopharmacology
- 24 Jan 2018 Status changed from recruiting to completed.